Skip to main content
Year archive

Inventiva — 2021 filings

All 75 regulatory filings released by Inventiva (IVA) in 2021, sourced directly from the official regulator.

75 Filings
2021 Period
2021 filings (75)
Filing Released Lang
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
Investor Presentation
2021-12-16 English
Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »
Report Publication Announcement
2021-12-16 French
Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranor
Earnings Release FY 2021
2021-12-06 French
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
Regulatory Filings
2021-12-06 English
Inventiva publie ses informations financières du 3ème trimestre 2021
Earnings Release 9M 2021
2021-11-10 French
Inventiva reports 2021 Third Quarter Financial Information
Earnings Release 9M 2021
2021-11-10 English
Inventiva organise un webcast avec des leaders d’opinion à l’occasion du congrès The Liver Meeting™ 2021 de l’AASLD
Regulatory Filings
2021-11-03 French
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
Regulatory Filings
2021-11-03 English
Inventiva annonce sa participation à plusieurs conférences investisseurs en novembre 2021
Investor Presentation
2021-10-29 French
Inventiva announces participation at several conferences in November 2021
Investor Presentation
2021-10-29 English
Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2
Regulatory Filings
2021-10-27 French
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
Regulatory Filings
2021-10-27 English
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Earnings Release FY 2021
2021-10-20 English
« The New England Journal of Medicine » publie les résultats de l’étude clinique de Phase IIb NATIVE d’Inventiva avec lanifibranor dans la NASH
Earnings Release FY 2021
2021-10-20 French
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
Investor Presentation
2021-10-18 English
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
Investor Presentation
2021-10-18 French
Franchissement de seuils
Major Shareholding Notification
2021-10-08 French
Inventiva annonce sa participation à plusieurs conférences investisseurs en octobre 2021
Regulatory Filings
2021-09-28 French
Inventiva announces participation at several investor conferences in October 2021
Regulatory Filings
2021-09-28 English
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
Capital/Financing Update
2021-09-23 English
Inventiva lève 30 millions de dollars dans le cadre de son programme At-The-Market pour des investisseurs institutionnels spécialisés existants et nouveaux
Capital/Financing Update
2021-09-23 French
Inventiva annonce la décision de la FDA que le statut « Fast Track » accordé à lanifibranor dans la NASH englobe le traitement de la NASH avec cirrhose compensée
Regulatory Filings
2021-09-21 French
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
Regulatory Filings
2021-09-21 English
Inventiva publie ses résultats financiers du 1er semestre 2021 et fait un point sur ses activités
Earnings Release H1 2021
2021-09-20 French
Inventiva reports 2021 first half financial results and provides a corporate update
Interim / Quarterly Report H1 2021
2021-09-20 English
RFS 2021
Interim / Quarterly Report H1 2021
2021-09-20 French
Inventiva annonce des recrutements clés pour accélérer le développement de lanifibranor dans la NASH
Board/Management Information
2021-09-16 French
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
Board/Management Information
2021-09-16 English
Présentation des résultats financiers du 1er semestre 2021 d’Inventiva
Report Publication Announcement
2021-09-10 French
Inventiva’s 2021 First-Half Financial Results Presentation
Earnings Release H1 2021
2021-09-10 English
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Regulatory Filings
2021-09-08 English
Inventiva annonce le lancement de l’étude clinique pivot de Phase III évaluant lanifibranor dans la NASH
Regulatory Filings
2021-09-08 French
Inventiva announces the implementation of an At-The-Market program in the United States
Capital/Financing Update
2021-08-02 English
Inventiva annonce la mise en place d’un programme At-The-Market aux Etats-Unis
Capital/Financing Update
2021-08-02 French
Inventiva présente ses informations financières du 1er semestre 2021
Earnings Release H1 2021
2021-07-28 French
Inventiva Reports First-Half of 2021 Financial Information
Earnings Release H2 2021
2021-07-28 English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Transaction in Own Shares
2021-07-22 French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Net Asset Value
2021-07-22 English
Inventiva annonce sa participation au « SVB Leerink CybeRx Series: Liver Disease Day »
Regulatory Filings
2021-06-15 French
Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
Regulatory Filings
2021-06-15 English
Inventiva annonce trois présentations scientifiques lors du EASL International Liver Congress™ 2021 et d’un webcast avec des leaders d’opinion
Regulatory Filings
2021-06-09 French
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
Report Publication Announcement
2021-06-09 English
Inventiva annonce sa participation à la « Jefferies Virtual Healthcare Conference »
Investor Presentation
2021-05-25 French
Inventiva to participate at the Jefferies Virtual Healthcare Conference
Investor Presentation
2021-05-25 English
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
Earnings Release Q1 2021
2021-05-12 English
Inventiva : information financière du 1er trimestre 2021 et point sur le partenariat avec AbbVie dans le domaine des maladies auto-immunes
Earnings Release Q1 2021
2021-05-12 French
Inventiva annonce sa participation à la « 7th Annual Truist Securities Life Sciences Summit »
Report Publication Announcement
2021-04-26 French
Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit
Regulatory Filings
2021-04-26 English
Nomination de Martine Zimmermann en tant qu’administratrice indépendante au Conseil d’Administration d’Inventiva
Board/Management Information
2021-04-19 French
Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
Board/Management Information
2021-04-19 English
Résultat des votes de l’Assemblée Générale Mixte du 16 avril 2021
Declaration of Voting Results & Voting Rights Announcements
2021-04-19 French
Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021
Declaration of Voting Results & Voting Rights Announcements
2021-04-19 English
Inventiva's Combined Shareholders Meeting of April 16, 2021 - Availability of the preparatory documents and methods for participating and voting
AGM Information
2021-03-25 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 10 mars 2021
Declaration of Voting Results & Voting Rights Announcements
2021-03-25 French
Statement of total voting rights and shares forming the company’s share capital on March 10th, 2021
Declaration of Voting Results & Voting Rights Announcements
2021-03-25 English
URD 2020
Annual Report FY 2020
2021-03-16 French
Inventiva annonce le dépôt de son Document d'Enregistrement Universel 2020 et de son Rapport Annuel 2020 (« Form 20-F »)
Report Publication Announcement FY 2020
2021-03-15 French
Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Report Publication Announcement
2021-03-15 English
URD 2020
Annual Report FY 2020
2021-03-15 French
Résultats annuels 2020 : Avancées majeures dans la NASH et visibilité financière significativement étendue suite au succès de l’introduction en bourse aux États Unis
Earnings Release FY 2020
2021-03-04 French
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
Earnings Release FY 2020
2021-03-04 English
Inventiva annonce une collaboration pour développer des biomarqueurs non-invasifs permettant l’identification de patients chez lesquels lanifibranor conduit à une résolution de la NASH et à une amélio
Regulatory Filings
2021-02-25 French
Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen
Earnings Release FY 2021
2021-02-25 English
Inventiva participera à plusieurs conférences investisseurs en mars 2021
Regulatory Filings
2021-02-24 French
Inventiva to participate at several investor conferences in March 2021
Report Publication Announcement
2021-02-24 English
Présentation des résultats financiers 2020 d’Inventiva
Earnings Release FY 2020
2021-02-23 French
Inventiva’s 2020 Full-Year Financial Results Presentation
Investor Presentation
2021-02-23 English
Exercice 2020 : Position de trésorerie et chiffre d’affaires
Earnings Release FY 2020
2021-02-11 French
Full-Year 2020: Cash position and revenues
Earnings Release FY 2020
2021-02-11 English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Net Asset Value
2021-01-15 French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Net Asset Value
2021-01-15 English
Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »
Report Publication Announcement
2021-01-06 English
Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »
Investor Presentation
2021-01-06 French
Inventiva annonce le design de son étude clinique de Phase III avec lanifibranor dans la NASH
Investor Presentation
2021-01-05 French
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
Regulatory Filings
2021-01-05 English